ALGN:NSD-Align Technology, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 621.87

Change

-3.64 (-0.58)%

Market Cap

USD 49.50B

Volume

0.52M

Avg Analyst Target

USD 687.92 (+10.62%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switze

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PODD Insulet Corporation

+5.66 (+2.12%)

USD18.28B 2,101.18 161.07
ABMD Abiomed, Inc

+1.84 (+0.57%)

USD14.60B 65.17 56.43
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.68 (+0.84%)

USD12.24B 61.16 31.63
TNDM Tandem Diabetes Care, Inc

+2.49 (+2.44%)

USD6.39B N/A N/A
SWAV ShockWave Medical, Inc

+7.69 (+4.52%)

USD6.11B N/A N/A
IART Integra LifeSciences Holdings ..

-0.39 (-0.55%)

USD6.02B 35.73 21.47
INMD InMode Ltd

+1.88 (+1.73%)

USD4.27B 49.55 42.31
LIVN LivaNova PLC

+3.91 (+4.77%)

USD4.01B 77.40 N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing ALGN

Symbol Name Weight Mer Price(Change) Market Cap
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+3.79 (+2.28%)

USD0.69B
RPG Invesco S&P 500 Pure Grow.. 0.00 % 0.35 %

+1.85 (+0.98%)

USD2.75B
DXG:CA Dynamic Active Global Div.. 0.00 % 0.81 %

-0.14 (-0.27%)

USD1.26B
DXU:CA Dynamic Active U.S. Divid.. 0.00 % 0.80 %

+0.01 (+0.02%)

USD0.27B
XDEW:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

+0.10 (+0.13%)

USD6.21B
XRMU:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

+0.17 (+0.46%)

USD0.14B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.59 %

+0.12 (+1.05%)

USD0.02B
XRSM:F Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

-0.05 (-0.16%)

USD0.14B
XRSM:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

+0.38 (+1.24%)

USD0.14B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.37% 55% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.37% 55% F 63% D
Trailing 12 Months  
Capital Gain 107.12% 77% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.12% 77% C+ 84% B
Trailing 5 Years  
Capital Gain 597.55% 96% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 597.55% 96% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 63.93% 84% B 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.93% 84% B 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 73.92% 41% F 23% F
Risk Adjusted Return 86.49% 96% A 89% B+
Market Capitalization 49.50B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 108.54 19% F 11% F
Price/Book Ratio 14.88 13% F 9% F
Price / Cash Flow Ratio 74.75 8% F 6% F
EV/EBITDA 77.15 33% F 12% F
Management Effectiveness  
Return on Equity 14.67% 95% A 82% B-
Return on Invested Capital 77.91% 98% A+ 98% A+
Return on Assets 7.51% 95% A 89% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.19 70% C- 55% F
Short Percent 1.92% 75% C 63% D
Beta 1.69 22% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.